A novel synthetic lethal target for ATM inhibitors in pancreatic cancer

A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 as a potential synthetic lethal marker for enhancing the efficacy of ATM inhibitors in pancreatic cancer treatment.

Ibutamoren mesylate by Lumos Pharma for Growth Hormone Deficiency: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

May 4, 2024

Eli Lilly chief scientist Daniel M. Skovronsky: Beware elected leaders who would weaken patents

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being

October 17, 2024

Strategies and innovations for reducing drug product loss in sterile filling – Pharmaceutical Technology

Share this article Credit: Shutterstock Sterile filling is a critical step in pharmaceutical primary packaging; the transfer of sterile drug product into its final primary

December 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.